"In light of the number of people with type 2 diabetes related to obesity, it's very important to investigate and explore any new tool that may have a positive effect on both weight and blood sugar," said Stephan Martin, MD, medical director of the West-German Diabetes and Health Centre in Düsseldorf, Germany, who conducted the study. "One of the most interesting findings to us was that Almased's positive effect on blood sugar was independent of its effect on weight loss."
Significant changes were seen at 12 weeks in the various study outcomes measured:
- Average insulin dose decreased from 147 to 65 units per day (p<0.0001).
- Weight decreased an average of 23 pounds (9%, p<0.0001).
- Average HbA1c, which is an overall measure of how well blood sugar is controlled, decreased from 8.8% to 8.1% (p=0.048).
- Fasting glucose, which is a measure of blood sugar after an eight-hour fast, decreased an average of 27.6 mg/dL (p=0.027).
- BMI decreased an average of 2.6 kg/m2 (p<0.0001).
- Average waist and hip circumferences decreased 2.8 inches (p=0.0003) and 1.3 inches (p=0.035), respectively.
- Triglycerides decreased an average of 70.3 mg/dL (p=0.0001) while HDL-cholesterol increased 2.2 mg/dL (p=0.049).
"Some people will be surprised that patients could stop insulin completely; we need to change the thinking that once insulin is started there is no way to stop it," said Dr. Martin. "Motivated patients who are committed to long-term dietary changes and increased physical activity can make a real change in their weight and metabolic measures."
"The problem of obesity and type 2 diabetes is large and growing," said Silke Ullmann, MPH, RD, LDN, of Almased USA. "We are committed to studying Almased to see how it may help people lose weight and gain better control of blood sugar levels."
Provided by Alembic Health Communications
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.